Entrada Therapeutics

TRDA · NASDAQ

$4.99+$0.17 (+3.53%)TodayMarket closed ·
Prev close $4.82

Who owns TRDA

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 62.4% of TRDA’s shares.

  • Baker Bros. Advisors LP13.1%
  • MPM Capital Inc.10.9%
  • 5AM Ventures10.0%
  • F. Hoffman La Roche, Ltd.6.6%
  • Next 6 largest institutions21.8%
  • All other shareholders37.6%
Top institutional holders of TRDA
HolderShares% of shares
Baker Bros. Advisors LP5.07M13.07%
MPM Capital Inc.4.23M10.90%
5AM Ventures3.88M9.99%
F. Hoffman La Roche, Ltd.2.57M6.62%
BlackRock Institutional Trust Company, N.A.2.19M5.65%
Merck & Co Inc1.74M4.48%
Vanguard Capital Management, LLC1.27M3.27%
MPM BioImpact LLC1.25M3.23%
TCG Crossover Management, LLC1.06M2.73%
Wellington Management Company, LLP954.42K2.46%

Largest mutual fund holders

Top mutual fund holders of TRDA
HolderShares% of shares
Vanguard Total Stock Market Index Fund953.73K2.46%
iShares Russell 2000 ETF764.69K1.97%
MEDICAL BioHealth454.56K1.17%
Fidelity Small Cap Index Fund319.18K0.82%
T. Rowe Price Health Sciences Fund295.98K0.76%

Insider trades

Form 4 filings by officers, directors and large holders

Over the last 6 months, insiders bought $29.32K (1 trade) and sold $10.95M (35 trades) of TRDA on the open market.

Latest TRDA insider transactions
InsiderTypeSharesValue
MPM BIOVENTURES 2018, L.P.Sale28.84K$205.61K
MPM BioVentures 2014, L.P.Sale28.84K$205.61K
MPM BIOVENTURES 2018, L.P.Sale192.50K$1.43M
MPM BioVentures 2014, L.P.Sale192.50K$1.43M
MPM BIOVENTURES 2018, L.P.Sale38.50K$273.74K
MPM BioVentures 2014, L.P.Sale38.50K$273.74K
MPM BIOVENTURES 2018, L.P.Sale32.26K$231.33K
MPM BioVentures 2014, L.P.Sale32.26K$231.33K
Sethuraman NatarajanTax withholding2.08K$14.85K
Dowden Nathan JTax withholding2.53K$18.06K

Short interest

Settled Sep 30, 2026

Shares short
2.99M
Days to cover
9.86
% of shares outstanding
7.70%
Average daily volume
303.17K
Change since last report
+8.9%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.